Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lance Sloan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Postgraduate Medicine|June 18, 2025
How treatment with SGLT2 inhibitors can help people with chronic kidney disease: a plain language summaryLance Sloan
Postgraduate Medicine|October 22, 2024
SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative reviewLance Sloan
Advances in Therapy|November 18, 2016
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An OverviewJaime A Davidson, Lance Sloan
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 5, 2026
Implementing the 2025 AACE Obesity Algorithm: Bridging Guidelines with Real-World Clinical PracticeBhargavi Patham, Lance Sloan, Julia Blanchette
The Journal of Family Practice|June 29, 2021
Management of Type 2 Diabetes in People With Renal ImpairmentAlice Yy Cheng, Lance Sloan, John Anderson
Diabetes, Obesity & Metabolism|January 15, 2024
The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative reviewLance Sloan, Alice Y Y Cheng, Javier Escalada, et al.
Current Medical Research and Opinion|March 11, 2008
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysisAli K Abu-Alfa, Lance Sloan, Chaim Charytan, et al.
Diabetes Care|October 4, 2012
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyJanet B McGill, Lance Sloan, Jennifer Newman, et al.
Pediatric Diabetes|April 12, 2022
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetesMargarita Barrientos-Pérez, Daniel S Hsia, Lance Sloan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 29, 2013
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trialJuan C Arjona Ferreira, Dalila Corry, Carl E Mogensen, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Postgraduate Medicine|June 18, 2025
How treatment with SGLT2 inhibitors can help people with chronic kidney disease: a plain language summaryLance Sloan
Postgraduate Medicine|October 22, 2024
SGLT2 inhibitors across the spectrum of chronic kidney disease: a narrative reviewLance Sloan
Advances in Therapy|November 18, 2016
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An OverviewJaime A Davidson, Lance Sloan
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|March 5, 2026
Implementing the 2025 AACE Obesity Algorithm: Bridging Guidelines with Real-World Clinical PracticeBhargavi Patham, Lance Sloan, Julia Blanchette
The Journal of Family Practice|June 29, 2021
Management of Type 2 Diabetes in People With Renal ImpairmentAlice Yy Cheng, Lance Sloan, John Anderson
Diabetes, Obesity & Metabolism|January 15, 2024
The role of basal insulins in the treatment of people with type 2 diabetes and chronic kidney disease: A narrative reviewLance Sloan, Alice Y Y Cheng, Javier Escalada, et al.
Current Medical Research and Opinion|March 11, 2008
The association of darbepoetin alfa with hemoglobin and health-related quality of life in patients with chronic kidney disease not receiving dialysisAli K Abu-Alfa, Lance Sloan, Chaim Charytan, et al.
Diabetes Care|October 4, 2012
Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled studyJanet B McGill, Lance Sloan, Jennifer Newman, et al.
Pediatric Diabetes|April 12, 2022
A study on pharmacokinetics, pharmacodynamics and safety of lixisenatide in children and adolescents with type 2 diabetesMargarita Barrientos-Pérez, Daniel S Hsia, Lance Sloan, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|January 29, 2013
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trialJuan C Arjona Ferreira, Dalila Corry, Carl E Mogensen, et al.
Pageof 1